Endometrial cancer (EC) is a prevalent cancer in women and is often linked to a high rate of recurrence and cancer-related deaths, making effective treatment crucial.
Conventional therapies like surgery, chemotherapy, and radiation face challenges, particularly due to drug resistance, emphasizing the need for new therapeutic options.
The review highlights recent advancements in small molecule targeted therapies, discussing their biological targets and potential for integrated diagnosis and treatment, along with the development of new agents that have fluorescence properties for improved clinical applications.